QuidelOrtho Corporation has completed its acquisition of LEX Diagnostics for approximately $100 million in cash. The deal expands QuidelOrtho's molecular diagnostics portfolio with the LEX VELO System, an ultra-fast PCR platform that delivers test results for Influenza A, Influenza B and COVID-19 in approximately six to ten minutes. The LEX VELO System received FDA 510(k) clearance and CLIA waiver in February 2026. Its cartridge-based design eliminates the need for external liquid handling, enabling rapid clinical decision-making in point-of-care environments. QuidelOrtho, a global provider of in vitro diagnostics, plans to launch the system commercially in the US later this year, with global expansion to follow pending regulatory approvals. The acquisition marks a key milestone in QuidelOrtho's strategy to accelerate growth in point-of-care molecular diagnostics.

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics (“LEX”) for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration (“FDA”) 510(k) clearance and CLIA waiver in February 2026.